

Published in final edited form as:

Nat Rev Cancer. 2008 November ; 8(11): 880–887. doi:10.1038/nrc2505.

VEGF-A splicing: the key to anti-angiogenic therapeutics?

Steven J. Harper and David O. Bates

Steven J. Harper and David O. Bates at the Microvascular Research Laboratories, Department of Physiology & Pharmacology, Bristol Heart Institute, School of Veterinary Science, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK

Abstract

The physiology of microvessels limits the growth and development of tumours. Tumours gain nutrients and excrete waste through growth-associated microvessels. New anticancer therapies target this microvasculature by inhibiting vascular endothelial growth factor A (VEGF-A) splice isoforms that promote microvessel growth. However, certain VEGF-A splice isoforms in normal tissues inhibit growth of microvessels. Thus, it is the VEGF-A isoform balance, which is controlled by mRNA splicing, that orchestrates angiogenesis. Here, we highlight the functional differences between the pro-angiogenic and the anti-angiogenic VEGF-A isoform families and the potential to harness the synthetic capacity of cancer cells to produce factors that inhibit, rather than aid, cancer growth.

The growth and progression of tumours, in line with that of all expanding cellular structures such as the placenta and the developing embryo, depends on a proliferating vasculature ensuring adequate supply of nutrients and efficient removal of waste products. The advent of anti-angiogenic therapies such as [sorafenib](#)¹, [sunitinib](#)² and [bevacizumab](#)^{3,4} stems from a huge leap in our mechanistic understanding of the initiation, development, refinement and maintenance of new vessels and microvessels. This in turn originates from the discovery in the 1980s by Ferrara⁵, Senger⁶ and Keck⁷ of the principal player in angiogenesis, vascular endothelial growth factor A ([VEGF-A](#), also referred to as VEGF). VEGF-A exists in multiple isoforms of variable exon content and strikingly contrasting properties and expression patterns. This range of products from the 8-exon *VEGF-A* gene on chromosome 6 renders VEGF-A biology complex (FIG. 1), and alterations in isoform expression in cancer may be instructive for other genes involved in malignant change in general⁸ and in the pro-angiogenic cascade in particular. Indeed, the products of *VEGF-A*, rather than just being targets for inhibition, may hold the key to impeding tumour growth and act as a model for controlling the qualitative expression of other malignancy-associated genes.

In tumours, and most other angiogenic situations, new vessel development is primarily dependent on this 46 kDa glycoprotein acting on its endothelial cell receptors VEGF receptor 1 ([VEGFR1](#)), [VEGFR2](#) and the co-receptor [neuropilin 1](#). This view is supported by the finding that even heterozygous *Vegfa* knockouts are embryonically lethal⁹. The first VEGF-A isoform described, VEGF-A₁₆₅ (REF. 5), has been extensively investigated for its function, signalling, expression and roles in cancer¹⁰. Other isoforms including VEGF-A₁₂₁, VEGF-A₁₄₅, VEGF-A₁₄₈, VEGF-A₁₈₃, VEGF-A₁₈₉ and VEGF-A₂₀₆, identified

© 2008 Macmillan Publishers Limited. All rights reserved

Correspondence to S.J.H. e-mail: s.harper@bristol.ac.uk.

Competing interests statement

The authors declare [competing financial interests](#): see web version for details.

between 1989 and 2003, are generated by alternative splicing of exons 6 and 7, which code for motifs that bind to the highly negatively charged glycosaminoglycan carbohydrate heparin and similar molecules. In 2002, an additional isoform was identified¹¹: VEGF-A_{165b}, which is generated by exon 8 distal splice site (DSS) selection. This DSS choice can also occur in conjunction with exon 6 and 7 inclusion or exclusion. It therefore became apparent that *VEGF-A* mRNA splicing generates two families of proteins that differ by their C' terminal six amino acids (FIG. 1), and these are termed VEGF-A_{xxx} (pro-angiogenic) and VEGF-A_{xxx}b (anti-angiogenic)¹², xxx denoting the amino acid number of the mature protein.

Details of the molecular control of C' terminal splice site choice (and the pro-angiogenic-anti-angiogenic balance) are emerging¹³ (FIG. 2). Upstream factors governing VEGF-A expression include hypoxia, cytokines, sex hormones, chemokines and growth factors (reviewed in REFS 10,14), although most studies have assessed VEGF-A expression using agents that would not distinguish between the two VEGF-A families. Subsequent downstream VEGF-A signalling of the conventional pro-angiogenic VEGF-A_{xxx} isoforms has been identified (reviewed in REFS 15,16) (FIG. 3a). Alterations in these pathways have not been identified in as much detail for the VEGF-A_{xxx}b family (FIG. 3b).

In this article we consider the significant functional differences between the isoform families and the progress made in determining the mechanistic differences between them.

Expression of VEGF-A_{xxx}b isoforms

Increased expression of VEGF-A appears to be a characteristic in several pathologies, including cancer, arthritis and cardiovascular disease, but it is upregulated from a basal level in normal tissues. The development of antibodies and probes that specifically detect VEGF-A_{xxx}b isoforms by enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, western blotting and quantitative PCR has revealed that basal expression is dominated by VEGF-A_{xxx}b isoforms in many tissues¹⁷. In human vitreous fluid, circulating plasma, urine, renal cortex, colonic epithelium, bladder smooth muscle, lung and pancreatic islets, VEGF-A_{xxx}b isoforms constitute more than or close to half of the total VEGF-A expressed^{12,17,18}. To date, the placenta, in which angiogenesis is known to occur, is the only normal tissue identified to have VEGF-A_{xxx}b constituting significantly less than half its total VEGF-A¹⁷.

In primary cultured cells, such as differentiated visceral glomerular epithelial cells (podocytes), retinal pigmented epithelial cells and colonic epithelial cells, VEGF-A_{xxx}b isoforms predominate^{13,19,20}. However, in melanoma, colorectal carcinoma and bladder cancer cells as well as proliferating dedifferentiated podocytes, VEGF-A_{xxx} isoforms comprise the majority of VEGF-A¹⁹⁻²¹.

VEGF-A_{xxx}b structure and properties

Receptor binding, downstream signalling and pharmacology

VEGF-A_{165b} differs from VEGF-A₁₆₅ only in the carboxy-terminal six amino acids, a change from CDKPRR to SLTRKD¹¹. The unique C'-terminal six amino acids encoded by exon 8b endow VEGF-A_{165b} (and other VEGF-A_{xxx}b isoforms) with radically different properties to those of VEGF-A₁₆₅. The key residue alterations are the loss of the cysteine and the replacement of the highly positively charged arginines present in VEGF-A₁₆₅ with neutral lysine-aspartic acid in VEGF-A_{165b}²². These differences have profound implications for structure (FIG. 4), receptor interaction (FIG. 5) and function (as discussed below). VEGF-A₁₆₅ binding to VEGFR2 and neuropilin 1 induces a conformational change

in VEGFR2 (REF. 23), which is thought to be similar to that of the ERBB2 receptor²⁴, resulting in internal rotation of the intracellular domain. VEGF-A₁₆₅ binding, after resulting in dimerization of the receptor, leads to re-positioning of the kinase domain by rotation to the inside of the dimer, and hence induces tyrosine autophosphorylation. By contrast, VEGF-A_{165b} is predicted not to have this full rotational effect and so autophosphorylation is not efficient (FIG. 5). Recent experiments from L. Claessen-Welsh's group in Uppsala, Sweden support this concept, showing that VEGFR2 is actively phosphorylated by VEGF-A_{165b} binding but on different tyrosine residues, suggesting it may not simply be an inactive competitive inhibitor²⁵. Phospho-peptide mapping and site-specific phospho-antibody experiments show that VEGF-A_{165b} only partially activates VEGFR2 suggesting a partial intracellular rotation, such that the kinase domain is activated but tyrosine 1054, which is in the kinase regulatory site, is not phosphorylated, presumably due to insufficient torsional rotation. This results in rapid closure of the ATP binding site of the kinase and rapid inactivation²⁵, leading to a poorly activated kinase and weak, transient phosphorylation of extracellular-signal-regulated kinase 1 (ERK1) and ERK2 (REF. 26) (FIG. 5). VEGF-A₁₆₅ also stimulates robust phosphorylation of tyrosine 1175, resulting in activation of phospholipase C γ , phosphoinositide 3-kinase and diacylglycerol production, and activation of the Raf-MEK-Erk pathway in a protein kinase C-dependent²⁷, Ras-independent manner²⁸ (FIG. 3). These events are crucial for the activation of pro-angiogenic gene expression in endothelial cells, particularly as they lead to the production of the matrix metalloproteinases that are required for invasion through the basement membrane and the initiation of endothelial cell migration and angiogenesis²⁹. Notably, VEGF-A_{165b} does not bind neuropilin 1, as the basic carboxy-terminal amino acids essential for neuropilin 1 binding are absent²². The functional difference between VEGF-A₁₆₅ and VEGF-A_{165b} might be determined by absence of neuropilin 1 co-signalling, or it might be due to unique downstream signalling resulting from the different tertiary structures of the neuropilin 1-VEGFR2-VEGF-A₁₆₅ triple dimer complex and the VEGFR2-VEGF-A_{165b} double dimer. This question remains to be clarified.

VEGF-A functions as a dimer. The theoretical formation of heterodimers — either of paired isoforms (for example, VEGF-A₁₆₅-VEGF-A_{165b}) or non-paired isoforms (for example, VEGF-A₁₂₁-VEGF-A_{189b}) — adds yet more layers of potential complexity to the subject. The existence of heterodimers *in vivo* is unproven and their subsequent signalling and function is speculative.

Effect of VEGF-A_{xxx}b on non-endothelial cells

VEGF-A has long been regarded as a family of pro-angiogenic, pro-permeability vasodilator peptides. Two key discoveries have emerged in recent years that have resulted in a radical re-evaluation of VEGF-A biology. One was the identification of the anti-angiogenic VEGF-A_{xxx}b family. Although, 6 years after its description, the number of papers on this anti-angiogenic family equate to 40% of those published in the 6 years after the first discovery of VEGF, this group of isoforms has yet to attract the attention of the majority of VEGF investigators. The reasons for this are unclear but may simply be because it has been overlooked in the vast VEGF-A literature (approximately 200 publications per month) or because the identification of this group has unpalatable implications for all of us. Academically it suggests additional layers of complexity and, in terms of resource allocation, the existence of VEGF-A_{xxx}b suggests that many of the thousands of published manuscripts on VEGF-A may, at best, need re-interpretation or, at worst, require repeating with reagents that differentiate between isoform families. As tools for investigating VEGF-A_{xxx}b isoforms (for example, antibodies, probes and ELISA kits) have now become available, our understanding of the role of VEGF-A_{xxx}b should become clearer.

The second revolution in VEGF-A biology has been that, despite its nomenclature, VEGF-A is not specific to endothelial cells and can also be vital in the function and maintenance of non-endothelial cells. Mutations in the hypoxia response element of the *Vegfa* promoter can, for example, result in a form of motor neuron disease in mice³⁰, which is not associated with angiogenesis. VEGF-A₁₆₅ was subsequently shown to be neuroprotective³⁰. Inhibition of VEGF-A also results in retinal neurotoxicity both *in vitro* and *in vivo*³¹ and proteinuria in humans³² and in rodents³³. This latter effect could be due to podocyte cytotoxicity, for which both VEGF-A₁₆₅ (REF. 34) and VEGF-A_{165b}¹⁸ are *in vitro* survival factors, perhaps through VEGF-A-dependent phosphorylation of nephrin³⁵. VEGF-A_{165b} also acts as a paracrine or autocrine survival factor. Treatment of podocytes, retinal pigmented epithelial cells or colonic adenoma cells *in vitro* with a neutralizing antibody to VEGF-A_{165b} that does not bind VEGF-A₁₆₅, even when present in 50-fold excess^{18,20,36}, results in increased cytotoxicity^{13,18,20}. Conversely, treatment of these cell types with VEGF-A_{165b} reduces cytotoxicity when induced by multiple agents^{13,18,20}. The receptor-mediated mechanism of action of VEGF-A_{165b}-dependent cytoprotection in epithelial cells has not been well defined and indeed may be cell-type-dependent and VEGFR-phenotype-dependent, but these results support the concept that VEGF-A_{165b} may elicit distinct signalling pathways.

Effect of VEGF-A_{165b} on angiogenesis and tumour growth

The properties of VEGF-A_{165b} have been published by nine laboratories worldwide using VEGF-A_{165b}-transfected cells^{20,36,37}, VEGF-A_{165b}-encoding adenoviral constructs³⁶ and recombinant human VEGF-A_{165b}^{38,39}.

VEGF-A₁₆₅ stimulates endothelial cell migration and proliferation *in vitro*, vasodilatation⁴⁰, increased endothelial monolayer permeability *in vitro*¹⁸, chronically increased vascular permeability *in vivo*⁴¹, *in vivo* angiogenesis⁴² and pathological retinal neovascularization *in vivo*⁴³. By stark contrast, VEGF-A_{165b} does not stimulate these responses, and inhibits several VEGF-A₁₆₅-mediated processes: endothelial cell migration *in vitro*¹¹, proliferation *in vitro*¹¹ and vasodilatation *ex vivo*¹¹. VEGF-A_{165b} does not increase chronic microvascular permeability *in vivo*⁴⁴ and reduces conditionally immortalized human glomerular endothelial cell monolayer permeability *in vitro*¹⁸. VEGF-A_{165b} also inhibits *in vivo* angiogenesis in the rat mesentery when VEGF-A₁₆₅ overexpression is driven by an adenoviral vector³⁶. In addition, VEGF-A_{165b} inhibits pathological angiogenesis in murine tumour models^{20,37,39}, physiological angiogenesis in mammary tissue in transgenic mice⁴⁵, VEGF-A₁₆₅-mediated angiogenesis in the chick chorioallantoic membrane assay²⁶ and VEGF-A₁₆₅-mediated angiogenesis in the rabbit corneal eye pocket model³⁶. Finally, recombinant human VEGF-A_{165b} inhibits hypoxia-mediated retinal angiogenesis *in vivo* in murine models of retinopathy of prematurity³⁸ and human tumour growth in mice³⁹.

Both VEGF-A₁₆₅ and VEGF-A_{165b} bind VEGFR2 with equal affinity^{20,36} but VEGF-A_{165b} fails to stimulate angiogenesis *in vivo*^{26,36,45}. These initial observations lent credence to the view that VEGF-A_{165b} was likely to demonstrate classical competitive 'key-in-the-lock' inhibition, even if the molecule was completely inert. However, further work by Ballmer-Hofer's group²⁶ has shown that a truncated isoform of VEGF-A₁₆₅, VEGF-A₁₅₉, which lacks the amino acids encoded by exons 8a and 8b, does not inhibit VEGF-A₁₆₅-mediated angiogenesis, despite binding to VEGFR2 and lacking angiogenic activity itself, which suggests that the presence of exon 8b in VEGF-A_{165b} may have a specific inhibitory contribution. Therefore, it is as yet unclear whether the profound difference in cellular behaviour induced by VEGF-A_{165b} relative to VEGF-A₁₆₅ is due to a qualitative alteration in signalling (that is, differing signalling molecules are used) or a quantitative alteration in signalling (that is, the downstream signalling is insufficient), or whether both mechanisms are functional. There is data supporting the quantitative hypothesis²⁵ but the qualitative hypothesis has only circumstantial evidence to date.

In tumours, overexpression of transfected VEGF-A₁₆₅b delays the growth of melanoma³⁶, kidney³⁷, colon²⁰, prostate³⁷ and Ewing sarcoma³⁷ tumours. Furthermore, recombinant human VEGF-A₁₆₅b inhibits developing and established solid tumour growth in nude mice when given subcutaneously or by intra-peritoneal injection³⁹. Tumours treated with VEGF-A₁₆₅b are paler, less haemorrhagic and visibly less vascularized, with reduced microvascular density and increased necrosis³⁹. Dose-response studies show complete inhibition of established tumour growth by 100 µg biweekly injection of recombinant VEGF-A₁₆₅b³⁹. Furthermore, parenteral treatment with recombinant human VEGF-A₁₆₅b can reduce the growth of disseminated metastatic melanoma tumours⁴⁶. All these data are consistent with a cancer-associated switch from anti- to pro-angiogenic VEGF-A isoform expression by alteration of splicing.

Heterogeneity of VEGF-A mRNA proximal splice site (PSS) selection in disease

Many cancers are associated with a switch from a VEGF-A_{xxx}b-dominated milieu in normal tissue to a proliferative phenotype in which VEGF-A_{xxx} isoforms dominate. In their study, Varey *et al.* showed by quantitative PCR and ELISA that the switch from VEGF-A_{xxx}b, which makes up 90% of the VEGF-A expressed by normal colonic tissue¹⁷, to VEGF-A_{xxx} (in other words, a switch from DSS to PSS selection) is variable in patients with colorectal cancer²⁰. Approximately 30% of patients still have a modest excess of VEGF-A_{xxx}b over VEGF-A_{xxx}, about half an excess of up to threefold VEGF-A_{xxx}, and the remainder a much greater VEGF-A_{xxx} excess, up to 60-fold²⁰. This switch to pro-angiogenic VEGF-A isoforms has also been shown at the mRNA level in prostate³⁷, renal¹¹ and bladder cancer²¹, and at the protein level in bladder cancer²¹ and metastatic but not non-metastatic melanoma⁴⁷. The study in melanoma demonstrated that primary melanomas from patients that later developed distant metastases expressed less VEGF-A₁₆₅b than those from patients that were disease-free 8 years later⁴⁷. Furthermore, a low level of VEGF-A₁₆₅b expression is a potential biomarker for poor prognosis in colonic carcinoma⁴⁸.

Therapeutic implications

Interaction with established anti-VEGF-A agents

VEGF-A₁₆₅b contains binding domains for the vast majority of anti-VEGF-A antibodies, including therapeutic antibodies such as bevacizumab and most of the commercially available antibodies for laboratory use. Western blotting and Biacore experiments show that VEGF-A₁₆₅b binds bevacizumab with the same affinity as VEGF-A₁₆₅ (REF. 20). However, a preliminary report suggests that pegaptinib, the VEGF-A aptamer (an oligonucleotide ligand that displays high-affinity binding to a molecular target), does not bind VEGF-A₁₆₅b⁴⁹, although similar data are not yet available for most other anti-VEGF-A agents, including VEGF-TRAP (aflibercept — a unique fusion protein that has a high affinity for all isoforms of VEGF-A as well as for placental growth factor), and VEGFR tyrosine kinase inhibitors (TKIs), such as sunitinib and sorafenib. However, it is possible that the combined effect of recombinant VEGF-A₁₆₅b and TKIs that target VEGFR2 may have increased efficacy over treatment with a VEGFR TKI alone, as VEGF-A₁₆₅b is not simply a non-specific inhibitor of VEGFR2 but can actively antagonize VEGFR2 angiogenic signalling²⁵ and possibly also VEGFR1 (REF. 44).

VEGF-A₁₆₅b expression has a profound effect on the efficacy of bevacizumab. In mice injected with VEGF-A₁₆₅b-expressing colonic cancer cells, the tumours grow more slowly than in those bearing VEGF-A₁₆₅-expressing cancer cells. However, the dose of bevacizumab required to prevent tumour growth in VEGF-A₁₆₅-expressing tumours had absolutely no effect on VEGF-A₁₆₅b-expressing tumours²⁰. This startling finding suggests that treatment of patients with tumours expressing significant levels of VEGF-A_{xxx}b with

bevacizumab may not be effective, because VEGF-A_{165b} will inhibit the effect of this anti-VEGF-A antibody. Conversely, this model would predict that bevacizumab treatment would be most effective in patients whose tumours produce an excess of VEGF-A_{xxx} isoforms.

Recombinant human VEGF-A_{165b}

It has yet to be established whether the inhibition of bevacizumab by VEGF-A_{165b} expression can be predicted by assessing the VEGF-A₁₆₅:VEGF-A_{165b} ratio in patients. If this is indeed the case, current assays for VEGF-A_{xxx}b will need to be developed for clinical use or standardized immunohistochemical procedures will be required. However, an alternative approach is that VEGF-A_{165b} (the most widely studied VEGF-A_{xxx}b isoform) or other VEGF-A_{xxx}b isoforms may be therapeutic themselves. In principle, VEGF-A_{165b} would have potential advantages over a number of existing anti-angiogenic therapies. These include its endogenous nature and the lack of side effects such as hypertension and proteinuria that are associated with the inhibition of VEGF-A_{xxx}³⁹. Anti-VEGF-A therapy has been shown to cause normal capillary loss⁵⁰, and endothelial cell-specific knockout of all VEGF-A isoforms (including VEGF-A_{165b}) results in adult mortality in mice due to endothelial cell apoptosis and subsequent haemorrhage⁵¹. There are therefore sound reasons to suspect that VEGF-A_{165b}-based therapy will be less problematic than agents that target all VEGF-A isoforms. Thus, the identification of VEGF-A_{xxx}-specific antagonists (for example, anti-exon 8a C'-terminal antibodies) may benefit from precise targeting. The next generation of anti-VEGF-A therapies might derive from such a design.

Tumour splicing hypothesis

The control of divergent physiological properties from one gene resides with mRNA splicing, stability and translation. The transcripts of the majority (70%) of human genes splice⁵², in that they code for multiple isoforms, many of which have strikingly different properties. Splicing is co-transcriptional, and the consensus sequences at the 5' and 3' sites are recognized by the splicing apparatus early in the splicing process — that is, the splicing choice occurs early in the birth of an RNA molecule. Splicing mechanisms in mammals are being elucidated using models such as *fibronectin*⁵³ and *β-globin*⁵⁴ and there is now considerable evidence that regulation of splicing is a key event in cancer progression^{8,55}. The process is mediated by splicing proteins, which form the spliceosome⁵⁶, and is regulated by splicing regulatory factors. Progress made in defining the mechanisms of *VEGF-A* exon 8 splice site choice¹³ are summarized in FIG. 2. Alternate 5' transcriptional start sites have been demonstrated for *VEGF-A57*, and these may result in alternative splicing through the recruitment of different splice factors. Other mechanisms, such as polypyrimidine tract binding protein-mediated repression of alternative exon splicing⁵⁸, are also possible regulators of *VEGF-A* splicing⁵⁹.

Thus, the cellular machinery underlying control of splice site choice, and hence which isoforms are expressed, are potential therapeutic targets, particularly as agents that inhibit the actions of specific splicing regulatory factors are now emerging⁶⁰. Regulation of alternative splicing is unlikely to be restricted to VEGF-A during angiogenesis. Many proteins in the angiogenic cascade have alternative splice variants with antagonistic properties. In active angiogenesis they all splice such that the pro-angiogenic isoforms predominate. VEGFR1 (REF. 61), VEGFR2 (REF. 62), *VEGFR3*, platelet-derived growth factor receptor-β (*PDGFRβ*), fibroblast growth factor receptor 1 (*FGFR1*), *FGFR2*, *FGFR4* (REF. 63) and neuropilin 1 (REF. 64) all have soluble splice variants that can, or are predicted to, act as natural inhibitors. Moreover, anti-angiogenic forms of *collagen XVII* (endostatin)⁶⁵ and *collagen IV* (tumstatin)⁶⁶ have also been characterized. Common splicing mechanisms allowing anti-angiogenesis to be switched to angiogenesis⁶⁷ in disease

or remodelling have been proposed⁶⁷, and these may extend to many non-angiogenesis-related proteins that also exist as multiple isoforms and drive tumour progression.

Indeed there are many non-angiogenic cancer-related genes that have splice isoforms with antagonistic properties and it is becoming increasingly apparent that similar factors can orchestrate the splicing of angiogenic and non-angiogenic malignancy-associated genes⁸. For example, exclusion of exon 3 of the FGFR1 in gliomas produces the tumour-promoting isoform FGFR1 β . This exon exclusion results from the loss of the splicing factor SRP55 (REF. 68), which also reduces *VEGF-A* C'-terminal DSS selection, shifting the VEGF-A_{xxx} versus VEGF-A_{xxx}b balance towards angiogenesis¹³.

Therefore, the dual phenomena of a molecular switch to stimulate unregulated malignant cell proliferation and the angiogenic switch as described by the late J. Folkman⁶⁹ may have different cellular mechanisms, but alternate splicing may well provide a mechanism explaining the connection between malignancy and angiogenesis, as Folkman hypothesized.

In summary, VEGF-A_{xxx}b isoforms are key regulators of angiogenesis in health and disease. Exogenously (intravenously) administered recombinant VEGF-A₁₆₅b appears to accumulate in tumours (presumably because it targets VEGFR2-bearing tumour microvessels) and therefore has increased tumour bio-availability³⁹. Thus, administration of recombinant VEGF-A_{xxx}b isoforms could be a novel therapeutic approach in the short term. However, the most effective but also the most challenging approach in the long term may be to allow cancer VEGF-A transcription to proceed unhindered but to control splicing such that the spliceosome opts for exon 8 DSS selection in place of exon 8 PSS selection. This would effectively cause the cancer to switch off its own nutrient supply. Indeed, given that the *VEGF-A* promoter contains a hypoxia response element⁷⁰, the more hypoxic the tumour became, the more effective this switch might be.

DATABASES

National Cancer Institute: <http://www.cancer.gov/>

[bladder cancer](#) | [colorectal carcinoma](#) | [Ewing sarcoma](#) | [kidney cancer](#) | [melanoma](#) | [prostate cancer](#)

National Cancer Institute Drug Dictionary: <http://www.cancer.gov/drugdictionary/>

[aflibercept](#) | [bevacizumab](#) | [sorafenib](#) | [sunitinib](#)

UniProtKB: <http://www.uniprot.org>

[\$\beta\$ -globin](#) | [collagen IV](#) | [collagen XVII](#) | [FGFR1](#) | [FGFR2](#) | [FGFR4](#) | [fibronectin](#) | [nephrin](#) | [neuropilin 1](#) | [PDGFR \$\beta\$](#) | [placental growth factor](#) | [SRP55](#) | [VEGFA](#) | [VEGFR1](#) | [VEGFR2](#) | [VEGFR3](#)

FURTHER INFORMATION

S. J. Harper's homepage: <http://www.mvrl.org>

References

1. Mendel DB, et al. *In vivo* antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. *Clin. Cancer Res.* 2003; 9:327–337. [PubMed: 12538485]

2. Motzer RJ, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. *N. Engl. J. Med.* 2007; 356:115–124. [PubMed: 17215529]
3. Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N. Engl. J. Med.* 2004; 350:2335–2342. [PubMed: 15175435]
4. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. *Semin. Oncol.* 2002; 29:10–14. [PubMed: 12516033]
5. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. *Biochem. Biophys. Res. Comm.* 1989; 161:851–858. [PubMed: 2735925]
6. Senger DR, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science.* 1983; 219:983–985. [PubMed: 6823562]
7. Keck PJ, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. *Science.* 1989; 246:1309–1312. [PubMed: 2479987]
8. Venables, JPE. *Alternative Splicing in Cancer.* Transworld Research Network; Kerala: 2006.
9. Ferrara N, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature.* 1996; 380:439–442. [PubMed: 8602242]
10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr. Rev.* 2004; 25:581–611. [PubMed: 15294883]
11. Bates DO, et al. VEGF_{165b}, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. *Cancer Res.* 2002; 62:4123–4131. [PubMed: 12124351]
12. Perrin RM, et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. *Diabetologia.* 2005; 48:2422–2427. [PubMed: 16193288]
13. Nowak DG, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by known splicing and growth factors. *J. Cell Sci.* in the press.
14. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nature Med.* 2000; 6:389–395. [PubMed: 10742145]
15. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. *Nature Rev. Mol. Cell Biol.* 2006; 7:359–371. [PubMed: 16633338]
16. Kerbel RS. Tumor angiogenesis. *N. Engl. J. Med.* 2008; 358:2039–2049. [PubMed: 18463380]
17. Bevan, HS.; Harper, SJ.; Bates, DO. *Angiogenesis: Basic Science and Clinical Applications.* Maragoudakis, ME.; Papadimitriou, E., editors. Transworld Research Network; Kerala: 2007. p. 1-26.
18. Bevan HS, et al. The alternatively spliced anti-angiogenic family of VEGF isoforms, VEGF_{xxx}b, in human kidney development. *Nephron Physiol.* in the press.
19. Cui TG, et al. Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF_{165b}) mRNA and protein. *Am. J. Physiol. Renal Physiol.* 2004; 286:F767–F773. [PubMed: 14644752]
20. Varey AH, et al. VEGF_{165b}, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. *Br. J. Cancer.* 2008; 98:1366–1379. [PubMed: 18349829]
21. Gopi SS, Zadeh MH, Harper SJ, Bates DO, Gillatt GA. Expression of anti-angiogenic isoform, VEGF_{165b} in transitional cell carcinoma of bladder. *BJU Int.* 2008; 101:29–30.
22. Cebe-Suarez S, et al. Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR. *FASEB J.* in the press.
23. Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. *Nature Struct. Mol. Biol.* 2007; 14:249–250. [PubMed: 17293873]
24. Burgess AW, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. *Mol. Cell.* 2003; 12:541–552. [PubMed: 14527402]
25. Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L. VEGF-A_{165b} is a weak *in vitro* agonist for VEGF receptor-2 due to lack of co-receptor binding and deficient regulation of kinase activity. *Cancer Res.* 2008; 68:4683–4692. [PubMed: 18559514]

26. Cebe Suarez S, et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. *Cell. Mol. Life Sci.* 2006; 63:2067–2077. [PubMed: 16909199]
27. Xia P, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. *J. Clin. Invest.* 1996; 98:2018–2026. [PubMed: 8903320]
28. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. *Oncogene.* 1999; 18:2221–2230. [PubMed: 10327068]
29. Lamoreaux WJ, Fitzgerald M, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells *in vitro*. *Microvasc. Res.* 1998; 55:29–42. [PubMed: 9473407]
30. Lambrechts D, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. *Nature Genet.* 2003; 34:383–394. [PubMed: 12847526]
31. Nishijima K, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. *Am. J. Pathol.* 2007; 171:53–67. [PubMed: 17591953]
32. Eremina V, et al. VEGF inhibition and renal thrombotic microangiopathy. *N. Engl. J. Med.* 2008; 358:1129–1136. [PubMed: 18337603]
33. Sugimoto H, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. *J. Biol. Chem.* 2003; 278:12605–12608. [PubMed: 12538598]
34. Foster RR, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. *Am. J. Physiol. Renal Physiol.* 2003; 284:F1263–F1273. [PubMed: 12620928]
35. Foster RR, Saleem MA, Mathieson PW, Bates DO, Harper SJ. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. *Am. J. Physiol. Renal Physiol.* 2005; 288:F48–F57. [PubMed: 15339792]
36. Woolard J, et al. VEGF_{165b}, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, *in vivo* effect on angiogenesis and endogenous protein expression. *Cancer Res.* 2004; 64:7822–7835. [PubMed: 15520188]
37. Rennel ES, et al. The endogenous anti-angiogenic VEGF isoform, VEGF_{165b} inhibits human tumour growth in mice. *Br. J. Cancer.* 2008; 98:1250–1257. [PubMed: 18349828]
38. Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA. VEGF_{165b}, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularisation in mice. *Mol. Vis.* 2006; 12:626–632. [PubMed: 16735996]
39. Rennel ES, et al. Recombinant human vascular endothelial growth factor (VEGF_{165b}) protein is an effective anti-cancer agent in mice. *Eur. J. Cancer.* 2008; 44:1883–1894. [PubMed: 18657413]
40. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. *Am. J. Physiol. Heart Circ. Physiol.* 1993; 265:H586–H592.
41. Bates DO, Curry FE. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. *Am. J. Physiol. Heart Circ. Physiol.* 1996; 271:H2520–H2528.
42. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. *J. Cell Biochem.* 1991; 47:211–218. [PubMed: 1791185]
43. Mitchell CA, et al. Unique vascular phenotypes following over-expression of individual VEGF-A isoforms from the developing lens. *Angiogenesis.* 2006; 9:209–224. [PubMed: 17109192]
44. Glass CA, Harper SJ, Bates DO. The anti-angiogenic VEGF isoform VEGF_{165b} transiently increases hydraulic conductivity, probably through VEGF receptor 1 *in vivo*. *J. Physiol.* 2006; 572:243–257. [PubMed: 16423853]

45. Qiu Y, et al. Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF_{165b}. *FASEB J.* 2008; 22:1104–1112. [PubMed: 18032632]
46. Budge JR, Fryer JD, Bates DO. Intraperitoneal administration of recombinant human VEGF_{165b} inhibits dissemination of metastatic melanoma cells *in vivo*. *Microcirculation.* 2008; 17:18–19.
47. Pritchard-Jones RO, et al. Expression of VEGF_{xxx}b, the inhibitory isoforms of VEGF, in malignant melanoma. *Br. J. Cancer.* 2007; 97:223–230. [PubMed: 17595666]
48. Diaz R, et al. p73 isoforms affect VEGF, VEGF_{165b} and PEDF expression in human colorectal tumors: VEGF_{165b} downregulation as a marker of poor prognosis. *Int. J. Cancer.* 2008; 123:1060–1067. [PubMed: 18546269]
49. Magnussen A, et al. VEGF_{165b} is more potent at inhibiting endothelial cell migration than Pegaptanib and is cytoprotective for retinal pigmented epithelial cells. *FASEB J.* 2008; 22:746.14.
50. Baffert F, L. T, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. *Am. J. Physiol. Heart Circ. Physiol.* 2006; 290:H547–H559. [PubMed: 16172161]
51. Lee S, et al. Autocrine VEGF signaling is required for vascular homeostasis. *Cell.* 2007; 130:691–703. [PubMed: 17719546]
52. Ghigna, C., et al. Alternative Splicing in Cancer. Venables, JP., editor. Transworld Research Network; Kerala: 2006. p. 197-208.
53. Muro AF, Iaconcig A, Baralle FE. Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and the 5' splicing site. *FEBS Lett.* 1998; 437:137–141. [PubMed: 9804187]
54. Schaal TD, Maniatis T. Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA. *Mol. Cell Biol.* 1999; 19:261–273. [PubMed: 9858550]
55. Venables JP. Aberrant and alternative splicing in cancer. *Cancer Res.* 2004; 64:7647–7654. [PubMed: 15520162]
56. Caceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. *Trends Genet.* 2002; 18:186–193. [PubMed: 11932019]
57. Neufeld G, et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. *Cancer Metastasis Rev.* 1996; 15:153–158. [PubMed: 8842486]
58. Amir-Ahmady B, Boutz PL, Markovtsov V, Phillips ML, Black DL. Exon repression by polypyrimidine tract binding protein. *RNA.* 2005; 11:699–716. [PubMed: 15840818]
59. Coles LS, et al. A multi-protein complex containing cold shock domain (Y-box) and polypyrimidine tract binding proteins forms on the vascular endothelial growth factor mRNA. Potential role in mRNA stabilization. *Eur. J. Biochem.* 2004; 271:648–660. [PubMed: 14728692]
60. Bakkour N, et al. Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. *PLoS Pathog.* 2007; 3:1530–1539. [PubMed: 17967062]
61. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. *Proc. Natl Acad. Sci. USA.* 1993; 90:10705–10709. [PubMed: 8248162]
62. Kou B, et al. *In vivo* inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. *Exp. Mol. Pathol.* 2004; 76:129–137. [PubMed: 15010291]
63. Jin P, et al. Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. *Arthritis Res. Ther.* 2008; 10:R73. [PubMed: 18593464]
64. Gagnon ML, et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: *In vivo* expression and antitumor activity. *Proc. Natl Acad. Sci. USA.* 2000; 97:2573–2578. [PubMed: 10688880]
65. Saarela J, Ylikarppa R, Rehn M, Purmonen S, Pihlajaniemi T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. *Matrix Biol.* 1998; 16:319–328. [PubMed: 9503365]
66. Mundel TM, Kalluri R. Type IV collagen-derived angiogenesis inhibitors. *Microvasc. Res.* 2007; 74:85–89. [PubMed: 17602710]

67. Bates DO, Harper SJ. Therapeutic potential of inhibitory VEGF splice variants. *Fut. Oncol.* 2005; 1:467–473.
68. Jin W, Cote GJ. Enhancer-dependent splicing of *FGFR1 α* -exon is repressed by RNA interference-mediated down-regulation of SRp55. *Cancer Res.* 2004; 64:8901–8905. [PubMed: 15604250]
69. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. *Ann. Surg.* 1972; 175:409–416. [PubMed: 5077799]
70. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. *Nature Med.* 2003; 9:677–684. [PubMed: 12778166]
71. Whittle C, Gillespie K, Harrison R, Mathieson PW, Harper SJ. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. *Clin. Sci. (Lond.)*. 1999; 97:303–312. [PubMed: 10464055]
72. Hirose Y, Tacke R, Manley JL. Phosphorylated RNA polymerase II stimulates pre-mRNA splicing. *Genes Dev.* 1999; 13:1234–1239. [PubMed: 10346811]
73. Koenigsberger C, Chicca JJ 2nd, Amoureux MC, Edelman GM, Jones FS. Differential regulation by multiple promoters of the gene encoding the neuron-restrictive silencer factor. *Proc. Natl Acad. Sci. USA.* 2000; 97:2291–2296. [PubMed: 10688910]
74. Starovasnik MA, et al. Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states. *J. Mol. Biol.* 1999; 293:531–544. [PubMed: 10543948]
75. Muller YA, Christinger HW, Keyt BA, de Vos AM. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å resolution: multiple copy flexibility and receptor binding. *Structure.* 1997; 5:1325–1338. [PubMed: 9351807]
76. Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA. Solution structure of the heparin-binding domain of vascular endothelial growth factor. *Structure.* 1998; 6:637–648. [PubMed: 9634701]
77. Keck RG, Berleau L, Harris R, Keyt BA. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. *Arch. Biochem. Biophys.* 1997; 344:103–113. [PubMed: 9244387]
78. Claffey KP, Senger DR, Spiegelman BM. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. *Biochim. Biophys. Acta Prot. Struct. Mol. Enzymol.* 1995; 1246:1–9.




Figure 1. Protein and mRNA products of human vascular endothelial growth factor A (VEGF-A)

a | Gene structure of human *VEGF-A*. *VEGF-A* spans 16,272 bp of chromosome 6p12 and consists of eight exons. Alternate 5' and 3' splice site selection in exons 6, 7 and 8 generate multiple isoforms. Exons 6 and 7 encode heparin binding domains. The transcriptional start site (TSS) and translational start site (ATG) in exon 1 are indicated. Alternative stop codons within exon 8 are also indicated (TGA1 and TGA2). **b** | Alternative splicing can occur either at the 5' donor splice site (for example, *VEGF-A*₁₈₉ versus *VEGF-A*₂₀₆) or the 3' acceptor splice site (for example, *VEGF-A*₁₈₉ versus *VEGF-A*₁₆₅). Two mRNA isoform families are generated. The pro-angiogenic isoforms (*VEGF-A*_{xxx}, left) are generated by proximal splice site (PSS) selection in exon 8 and the anti-angiogenic family (*VEGF-A*_{xxx}*b*, right) from exon 8 distal splice site (DSS) choice. Thus, *VEGF-A*₁₆₅, formed by PSS selection in exon 8, has *VEGF-A*_{165b} as its DSS sister isoform11, the DSS-selected mRNA encoding a protein of exactly the same length. Exon 6a' occurs in *VEGF-A*₁₈₃ as a result of a conserved alternative splicing donor site in exon 6a and is 18 bp shorter than full-length exon 6a.

*VEGF-A*₁₄₈ is a truncated isoform splicing from exon 7a into exon 8a out of frame and resulting in a premature stop codon71. *VEGF-A*_{206b} has not yet been identified. **c** | Protein structure of VEGF-A containing the dimerization sites and binding sites for heparin, VEGF-A receptor 1 (VEGFR1; encoded by exon 3) and VEGFR2 (encoded by exon 4), which are present in all isoforms. The six amino acids at the extreme carboxyl terminus of the protein can be either pro-angiogenic (CDKPRR, encoded by exon 8a) or anti-angiogenic (SLTRKD, encoded by exon 8b). The epitopes recognized by most commercial antibodies are in the region of the VEGF-A receptor-binding domains, present in VEGF-A isoforms of both families. UTR, untranslated region.




Figure 2. Vascular endothelial growth factor A (VEGF-A) C' terminal splicing regulation

a | The C' terminal domain of RNA polymerase II (Pol II) interacts with both transcription factors (TFs) and splicing factors (SFs). SFs are recruited to the transcriptional machinery owing to their interaction with Pol II^{72,73}. These SFs recognize *cis*-acting RNA splicing sequences in the pre-mRNA and both splicing sites (SS) — 5' donor (5' SS) or 3' acceptor sites — can be recognized. Both 3' proximal SS (3' PSS) and distal SS (3' DSS) are indicated. The particular splicing factors recruited are dependent on the sequence. These SFs can be regulated by SF kinases (SFKs), which are regulated by cell signalling molecules (CSMs) downstream of growth factors (GFs). **b** | Regulation of VEGF-A C' terminal PSS selection by insulin-like growth factor (IGF). IGF activates protein kinase C (PKC), which results in phosphorylation of SR protein kinases (SRPKs). These can activate the ASF-SF2 splicing factor, which favours PSS selection. This process may be dependent on the presence of hypoxia-inducible factor (HIF), a transcription factor involved in *VEGF-A_{xxx}* upregulation¹³. Other SFs and kinases may also be involved in PSS and DSS selection, denoted by '??'. **c** | Factors affecting VEGF-A C' terminal DSS selection. Transforming growth factor β 1 (TGF β 1) results in p38 mitogen-activated protein kinase activation and subsequent activation of the kinases CLK1 and CLK4. CLK1 and CLK4 phosphorylate the splicing factor SRP55, resulting in DSS selection and production of *VEGF-A_{xxx}b*¹³. It is also possible that ASF-SF2 is inactivated by CLK1 and CLK4, or that phosphorylation of the SFs could change their location, degradation or binding affinity. This scheme summarizes the limited data available.




Figure 3. Signalling pathways downstream of vascular endothelial growth factor (VEGF-A)_{xxx} and VEGF-A_{xxx}b

a | The VEGF-A_{xxx}-mediated angiogenic response acts primarily through VEGF receptor 2 (VEGFR2) to initiate multiple downstream pathways^{15,16}. **b** | VEGF-A_{165b} results in transient, weak phosphorylation and the downstream signalling (denoted “?”) from such qualitatively different phosphorylation is largely unknown (see REF. 25 for details). Erk, extracellular signal-regulated kinase; HSP27, heat shock protein 27; NOS3, endothelial nitric oxide synthase; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; RAC, Ras-related C3 botulinum toxin substrate; PLCγ, phospholipase Cγ; SHB, SH2 domain-containing adaptor protein B; SHC1, SH2 domain-containing transforming protein 1; VRAP, VEGF receptor-associated protein.




Figure 4. The structure of vascular endothelial growth factor A (VEGF-A)

a | Crystal structure of amino acids 4-108 of VEGF-A, which are present in all isoforms. The crystal structure of the full-length VEGF-A protein is not known as a hinge region after amino acid 108 prevents crystallization. Modified, with permission, from REF. 74 © 1999 Elsevier B.V. **b** | Amino acids 4-108 of VEGF-A are shown along with the crystal structure of the final 55 residues. Crystallization of the final 55 residues of VEGF-A₁₆₅ indicates two cysteine (C)-bonded double anti-parallel β sheet structures (brown arrows) separated by an α helix (blue cylinder). This structure is highly mobile and rotates around the hinge, and could pass through the VEGF receptor 2 (VEGFR2) binding region but not the VEGFR1 region (yellow circles)^{75,76}. **c** | Proposed structure of amino acids 108-165 of VEGF-A₁₆₅. The C' terminal six residues include a cysteine with two positively charged arginines (RR) that are proposed to interact with the VEGFR binding domain²² to activate intracellular torsional rotation of VEGFR2. The RR motif therefore acts as a molecular switch by inducing a conformational change in VEGFR2. A disulphide bond⁷⁷ (shown in orange) between cysteines 146 and 160 is required for VEGF-A₁₆₅ activity⁷⁸ and ensures that the C terminus is maintained at close proximity to the neuropilin 1 binding domain (NPBD). **d** | Proposed structure of amino acids 108-165 of VEGF-A_{165b}. The C' terminal cysteine and the positively charged RR motif present in VEGF-A₁₆₅ are replaced by a serine (S) and a neutral DK motif on VEGF-A_{165b} respectively. Although the VEGFR binding domain is present, the cysteine disulphide bond is absent. Thus, the molecular interaction with VEGFR is likely to be significantly different.




Figure 5. Vascular endothelial growth factor A (VEGF-A)_{165b} and VEGF-A₁₆₅ interaction with VEGF receptor 2 (VEGFR2)

a | The VEGFR2 binding site of VEGF-A₁₆₅ interacts with the VEGFR2 extracellular domain. VEGF-A₁₆₅ functions as a dimer and promotes the formation of VEGFR2 dimers (only one receptor is shown here for clarity) resulting in activation of the split kinase domains (green lines) and the phosphorylation of tyrosine residues 951, 1152 and 1214 (orange) and 1054 (purple). The charged residues at the carboxy-terminal end of the VEGF-A₁₆₅ molecule (omitted for clarity) are required for VEGFR activation and, in receptor tyrosine kinases, this is thought to occur through torsional rotation of the intracellular domain bringing together the split kinase domains. Tyrosine 1054 is located at the mouth of the ATP binding pocket of the tyrosine kinase and, once phosphorylated, prevents the binding pocket from closing, thus resulting in a stable open structure. This results in

formation of a persistently functional kinase from the split kinase domains, resulting in sustained *cis*- and *trans*- phosphorylation of the tyrosine residues on the intracellular tail, even in the presence of phosphatases. Robust tyrosine phosphorylation also results in the activation of angiogenic signalling pathways (FIG. 3). **b** | VEGF-A_{165b} binds the VEGFR2 binding site with equal affinity to VEGF-A₁₆₅ but does not bind neuropilin 1 (NRP1). The C' terminus of VEGF-A_{165b} is neutral and there is insufficient torsional rotation for tyrosine 1054 to be phosphorylated, although weak phosphorylation of the other tyrosines can occur. Thus, the ATP binding pocket closes and the phosphorylated tyrosines can be rapidly dephosphorylated by phosphatases and trafficked much more quickly. As a result, angiogenic signalling pathways are not activated²⁵.